Experts endorse low-sodium salt substitutes to cut India’s hypertension burden

Consensus calls for nationwide adoption of potassium-enriched salt to reduce cardiovascular disease risk

Bayer flags major Phase III results for stroke prevention drug asundexian

The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy

DKSH and Sanofi join forces to expand access to cardio & diabetes treatments in Southeast Asia

The aim is to bolster healthcare delivery in a region increasingly burdened by chronic disease

MSN Laboratories launches SEMABEST, India-made semaglutide pen at nearly 50% lower price

CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing

Novartis expands global push to close life-saving gaps in heart disease & cancer care by 2030

Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups

Eli Lilly launches once-daily weight-loss pill Foundayo

The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions

Lupin Foundation expands NCD care access in Rajasthan with new diagnostic corners

The initiative is aimed at strengthening the district-level screening and chronic disease management infrastructure

Cadila Pharma launches triple-combination therapy for stronger BP control

The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms

Stereotaxis bags FDA clearance for next-gen cath lab tech

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market